Barinthus BiotherapeuticsSTU:2AB 14 EV-to-EBIT is 0.59 as of Jul. 05, 2026, which is 13% above its 10-year median of 0.52. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.94. The stock has 1 warning sign investors should review. Among 368 Biotechnology companies, Barinthus Biotherapeutics ranks better than 82.88% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Barinthus Biotherapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was €-28.18 Mil.
Barinthus Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-45.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics EV-to-EBIT Related Terms
Barinthus Biotherapeutics EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: EV-to-EBIT Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's EV-to-EBIT falls into.
Barinthus Biotherapeutics's current Enterprise Value is €-26.62 Mil.
Barinthus Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-45.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a EV-to-EBIT of 0.59 as of Jul. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Barinthus Biotherapeutics and its competitors. This is 13% above median its historical median of 0.52. According to the industry distribution chart, Barinthus Biotherapeutics ranks #63 out of 368 companies in the Biotechnology industry, placing it in the top 17.1%.
Is Barinthus Biotherapeutics' EV-to-EBIT too high?
Barinthus Biotherapeutics' current EV-to-EBIT of 0.59 is 13% above median its 10-year median of 0.52. The Biotechnology industry median EV-to-EBIT is 15.08. Barinthus Biotherapeutics' value of 0.59 is 96.1% below this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #63 out of 368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' EV-to-EBIT compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #63 out of 368 companies for EV-to-EBIT. This places Barinthus Biotherapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.08. Barinthus Biotherapeutics' value of 0.59 is 96.1% below this benchmark. While the company's 10-year median is 0.52 vs. the industry median of 15.08, Barinthus Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.08, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current EV-to-EBIT of 0.59 is 96.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current EV-to-EBIT is 0.59, which is 13% above median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current EV-to-EBIT of 0.59. The stock's GF Value™ is €0.94, compared to a current price of €0.52 — trading 44.7% below its estimated fair value. The current EV-to-EBIT is 0.59, which is 13% above median its 10-year median of 0.52 and 96.1% below the Biotechnology industry median of 15.08. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current EV-to-EBIT is 0.59 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.52 is trading 44.7% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
EV-to-EBIT: 0.59 (13% above median its 10-year median of 0.52)
GF Value™: €0.94 vs. price of €0.52 (44.7% below fair value)
Industry Position: 96.1% below the Biotechnology median (#63 of 368)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
